Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 39.00
+1.60 (4.28%)
May 29, 2026, 1:30 PM CST
Tanvex BioPharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -1,423 | -1,500 | -1,382 | -2,137 | -1,641 | -1,543 |
Depreciation & Amortization | 311.7 | 320.63 | 287.56 | 323.59 | 280.01 | 241.43 |
Other Amortization | 46.1 | 46.1 | 1.48 | 1.24 | 1.55 | 2.15 |
Loss (Gain) From Sale of Assets | 40.52 | 46.91 | -0.08 | 2.87 | 7.21 | 0.94 |
Asset Writedown & Restructuring Costs | - | 49.19 | - | 8.67 | - | - |
Stock-Based Compensation | 10.82 | 9.07 | -2.16 | 326.61 | 67.55 | 52.95 |
Provision & Write-off of Bad Debts | -4.8 | 6.47 | - | - | - | - |
Other Operating Activities | -0.52 | -3.15 | 17.88 | -1.23 | - | -90.2 |
Change in Accounts Receivable | -37.06 | 211.25 | 9.33 | -9.06 | 2.19 | -2.52 |
Change in Inventory | -141.26 | -157.92 | -109.55 | 62.56 | -80.51 | -40.25 |
Change in Accounts Payable | 46.42 | 99.59 | - | 33.41 | -15.59 | -66.97 |
Change in Unearned Revenue | 171.14 | -68.36 | -0.56 | -10.93 | 28.07 | - |
Change in Other Net Operating Assets | -45.92 | -65.07 | 27.05 | -35.98 | 16.82 | 58.67 |
Operating Cash Flow | -1,026 | -1,005 | -1,151 | -1,435 | -1,334 | -1,387 |
Capital Expenditures | -835.37 | -668.26 | -105.91 | -71.02 | -93.5 | -29.82 |
Sale of Property, Plant & Equipment | 11.97 | 12.91 | 0.14 | 6.33 | 1.82 | 6.7 |
Sale (Purchase) of Intangibles | -2.48 | -1.94 | -4.86 | -0.32 | -2.58 | -0.52 |
Investment in Securities | 0.3 | 5 | - | - | - | - |
Other Investing Activities | -55.01 | 954.1 | 1.38 | -18.57 | -3.09 | -1.04 |
Investing Cash Flow | -880.59 | 301.8 | -109.25 | -83.57 | -97.35 | -24.68 |
Short-Term Debt Issued | - | 30 | 377.65 | - | - | - |
Total Debt Issued | 135 | 30 | 377.65 | - | - | - |
Short-Term Debt Repaid | - | - | -377.65 | - | - | - |
Long-Term Debt Repaid | - | -156.67 | -184.58 | -127.67 | -130.53 | -93.11 |
Total Debt Repaid | -174.91 | -156.67 | -562.23 | -127.67 | -130.53 | -93.11 |
Net Debt Issued (Repaid) | -39.91 | -126.67 | -184.58 | -127.67 | -130.53 | -93.11 |
Issuance of Common Stock | 1,255 | 1,264 | 1,440 | 1,207 | 7.24 | 1,690 |
Other Financing Activities | 1.72 | 0.22 | - | - | - | - |
Financing Cash Flow | 1,217 | 1,138 | 1,255 | 1,080 | -123.29 | 1,597 |
Foreign Exchange Rate Adjustments | 54.96 | 67.64 | 0.98 | 33.91 | 117.75 | -31.25 |
Net Cash Flow | -634.95 | 501.75 | -3.79 | -405.48 | -1,437 | 154.37 |
Free Cash Flow | -1,861 | -1,674 | -1,257 | -1,506 | -1,427 | -1,417 |
Free Cash Flow Margin | -384.63% | -417.41% | -3623.36% | -2452.94% | -6370.97% | -26208.75% |
Free Cash Flow Per Share | -7.29 | -6.83 | -8.09 | -11.69 | -12.14 | -13.05 |
Cash Interest Paid | 47.23 | 47.23 | 53.34 | 57.38 | 54.72 | 45.81 |
Cash Income Tax Paid | 0.83 | 0.83 | 1.02 | 0.88 | 0.02 | 0.02 |
Levered Free Cash Flow | -1,433 | -1,111 | -792.54 | -713.06 | -844.23 | -819.13 |
Unlevered Free Cash Flow | -1,404 | -1,082 | -759.2 | -677.19 | -810.03 | -790.24 |
Change in Working Capital | -6.68 | 19.49 | -73.73 | 39.99 | -49.03 | -51.08 |